SAR.L

Sareum Holdings Plc
Sareum Holdings PLC - Results of AGM
19th December 2024, 16:07
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8213Q
Sareum Holdings PLC
19 December 2024
 

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 19 December 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy.

 

Details of the proxy voting results are shown in the table below. 

 

Ordinary Resolutions

Votes For

%

Votes Against

%

Votes Total

% of ISC Voted

Votes Withheld

1. Receive the financial statements for the year

11,916,088

99.38

74,805

0.62

11,990,893

9.61%

163,189

2. Receive and approve the Directors' Renumeration Report for the year

11,800,364

98.55

174,011

1.45

11,974,375

9.60%

179,707

3. Re-elect Mr Clive Birch as Director of the Company

10,443,572

92.12

893,439

7.88

11,337,011

9.09%

817,071

4. Re-elect Dr Michael Owen as Director of the Company

10,443,672

92.12

893,339

7.88

11,337,011

9.09%

817,071

5. Re-appoint Shipleys LLP as auditor

11,775,627

98.70

154,926

1.30

11,930,553

9.56%

223,529

6. Authorise the audit committee to determine auditor renumeration

11,856,252

99.29

84,641

0.71

11,940,893

9.57%

213,189

7. Directors' authority to allot new shares

11,538,681

96.23

451,872

3.77

11,990,553

9.61%

163,529

Special Resolution








8. Directors' authority to disapply pre-emption rights

11,522,085

96.30

442,974

3.70

11,965,059

9.59%

189,023

9. Authority to hold general meetings

11,893,866

99.29

84,805

0.71

11,978,671

9.60%

175,411

 

The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)

 

For further information, please contact: 

Sareum Holdings plc

Stephen Parker, Executive Chaiman

 

 

01223 497700

ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

 

 

020 7409 3494

Oberon Capital (Joint Broker)

Mike Seabrook / Nick Lovering

 

 

020 3179 5300

Hybridan LLP (Joint Broker)

Claire Noyce

 

ICR Healthcare (Financial PR)

Jessica Hodgson / Davide Salvi / Kumail Walijee

 

 

020 3764 2341

 

 

020 3709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

- Ends -

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFLFIRFRLALIS]]>
TwitterFacebookLinkedIn